Bullish & Foolish
Full TELO fundamentals All 466 on the Survival Watch

TELOTelomir Pharmaceuticals, Inc.

Is Telomir Pharmaceuticals struggling financially?

Yes, by its own account. Telomir Pharmaceuticals told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

10/100

Critical

Sector
Biotech/Pharma
Market cap
$77.7M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$8.2M

What Telomir Pharmaceuticals told the SEC

…hand to support its operations for at least the 12 months following the date these unaudited condensed financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of twelve months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash…

Telomir Pharmaceuticals, Inc., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 57.5% share-count increase The company issued stock. Each share now owns 36.5% less of the business than a year ago, before any change in the price.
  • Cash burn is increasing It is spending 10% more cash per year than it was, so the runway above shortens even if nothing else changes.

Other Biotech/Pharma companies that filed the doubt